Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Mastocytosis, Systemic 1Arthritis, Rheumatoid 1

Interventions

midostaurin 2avapritinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1nilotinib 1masitinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Interviews as Topic 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Calcium Dobesilate 1Brentuximab Vedotin 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mastocytosis, Systemic × sarilumab × Clear all
NCT03770273 2024-12-17

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 13 charts
Myeloid

Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡